IRIS
ROSSI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.227
AS - Asia 1.945
EU - Europa 931
SA - Sud America 445
Continente sconosciuto - Info sul continente non disponibili 174
AF - Africa 48
OC - Oceania 7
Totale 6.777
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.082
SG - Singapore 868
IT - Italia 488
CN - Cina 460
BR - Brasile 342
VN - Vietnam 218
IN - India 186
DE - Germania 100
SE - Svezia 100
CA - Canada 88
GB - Regno Unito 80
HK - Hong Kong 46
BD - Bangladesh 45
AR - Argentina 42
FI - Finlandia 34
MX - Messico 23
NL - Olanda 23
JP - Giappone 22
EC - Ecuador 20
FR - Francia 20
EU - Europa 18
RU - Federazione Russa 16
ID - Indonesia 14
RO - Romania 13
UA - Ucraina 13
ES - Italia 12
IQ - Iraq 12
ZA - Sudafrica 12
PK - Pakistan 10
TR - Turchia 10
CL - Cile 9
PY - Paraguay 9
VE - Venezuela 9
CR - Costa Rica 8
AT - Austria 7
CZ - Repubblica Ceca 7
JO - Giordania 7
SC - Seychelles 7
TW - Taiwan 7
AU - Australia 6
CO - Colombia 6
UZ - Uzbekistan 6
EG - Egitto 5
GT - Guatemala 5
IR - Iran 5
MA - Marocco 5
NP - Nepal 5
PE - Perù 5
PL - Polonia 5
HN - Honduras 4
SA - Arabia Saudita 4
TN - Tunisia 4
AZ - Azerbaigian 3
CH - Svizzera 3
DZ - Algeria 3
KE - Kenya 3
KZ - Kazakistan 3
MY - Malesia 3
PA - Panama 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
BW - Botswana 2
CG - Congo 2
DO - Repubblica Dominicana 2
GR - Grecia 2
JM - Giamaica 2
KR - Corea 2
LT - Lituania 2
NI - Nicaragua 2
PH - Filippine 2
PR - Porto Rico 2
SN - Senegal 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
ET - Etiopia 1
GE - Georgia 1
GP - Guadalupe 1
IE - Irlanda 1
IL - Israele 1
LB - Libano 1
LC - Santa Lucia 1
MD - Moldavia 1
MN - Mongolia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SI - Slovenia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.623
Salva come PNG Salva come JPEG
Città #
San Jose 608
Ashburn 301
Singapore 292
Chandler 230
Dallas 174
Council Bluffs 163
Santa Clara 156
Hefei 126
Bengaluru 123
Milan 122
Princeton 108
Lawrence 106
Ho Chi Minh City 89
Beijing 76
Chicago 60
Munich 59
Wilmington 58
Catanzaro 49
London 49
Phoenix 47
Hong Kong 44
New York 44
Des Moines 40
Hanoi 37
Los Angeles 34
Ottawa 28
São Paulo 28
Turku 23
Rome 22
Montreal 19
Brooklyn 18
Naples 16
Tokyo 15
Toronto 14
Guangzhou 13
Redwood City 13
Pune 12
Boardman 11
Da Nang 11
Helsinki 11
Rio de Janeiro 11
San Francisco 11
Shanghai 11
Haiphong 10
Redmond 10
The Dalles 10
Atlanta 9
Columbus 9
Porto Alegre 9
Biên Hòa 8
San José 8
Amman 7
Boston 7
Brasília 7
Buffalo 7
Charlotte 7
Guayaquil 7
Miami 7
Can Tho 6
Chennai 6
Cosenza 6
Horia 6
Jiaxing 6
Leawood 6
Manchester 6
Mexico City 6
Mountain View 6
Orem 6
Tashkent 6
Timisoara 6
Ahmedabad 5
Augusta 5
Baghdad 5
Belo Horizonte 5
Guatemala City 5
Kulgam 5
Lima 5
Olomouc 5
Parma 5
Quito 5
Reggio Calabria 5
Salvador 5
San Nicola Manfredi 5
Zhengzhou 5
Ankara 4
Asunción 4
Bari 4
Berlin 4
Birigui 4
Curitiba 4
Dhaka 4
Florianópolis 4
Goiânia 4
Hanover 4
Jakarta 4
Lecce 4
Norwalk 4
Paris 4
San Antonio 4
San Diego 4
Totale 3.810
Salva come PNG Salva come JPEG
Nome #
A Comprehensive Safety Evaluation of Trabectedin and Drug-Drug Interactions of Trabectedin-Based Combinations 181
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 154
miR-22 suppresses DNA ligase III addiction in multiple myeloma 116
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study 98
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 91
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 84
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 84
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 83
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 82
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 81
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 80
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 79
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 79
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 78
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 77
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 76
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. 75
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 75
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 71
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 70
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 70
Enlarging the clinical spectrum of chorea-acanthocytosis 69
Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia 69
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 68
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 68
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 67
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 67
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice 67
Mir-221/222 are promising targets for innovative anticancer therapy 65
CD7+ acute leukemia switching from a lymphoid to a myeloid phenotype 65
Mycosis fungoides and gastric t-cell lymphoma: A case report 65
Depression of lymphocyte activity during cutaneous leishmaniasis: a case report. 64
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 63
The non-coding RNA landscape of plasma cell dyscrasias 63
Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: Insights fromthe EYESHOT study 62
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 61
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 61
Role of Nucleophosmin in embryionic development and tumorigenesis 60
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 59
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 59
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells 58
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 57
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence 56
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 55
Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy 55
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials 54
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 54
Dendritic cells have the option to express IDO-mediated suppression or not 53
Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo 53
miR-22 suppresses DNA ligase III addiction in multiple myeloma. 53
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 52
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 51
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 51
Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and adaptive Immunity 51
Daunorubicina liposomiale in ematologia 50
Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease 50
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells 50
Immunologic microenvironment and personalized treatment in multiple myeloma 48
Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation) 48
Mouse models of Multiple Myeloma: technologic platforms and perspectives 47
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 47
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 46
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 46
CAR-T Cell Therapies in B-Cell Acute Lymphoblastic Leukemia: Emerging Data and Open Issues 46
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 45
Genetics and molecular profiling of multiple myeloma: Novel tools for clinical management? 45
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress 44
Multiple myeloma-related bone disease: state-of-art and future treatments 44
Osteonecrosis of the Jaw Prevention and Management in Modern Oncology 44
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 44
Translational Studies on the Bone Marrow Microenvironment in Multiple Myeloma: Experimental Models and Emerging Therapeutical Strategies 43
Molecular Targets for the Treatment of Multiple Myeloma 43
null 43
CFD analysis of different arterial cannulation site during Heart Surgery with Cardioplumnonary Bypass 43
Emerging Role of MicroRNAs in the Pathophysiology of Immune System 42
Multiple Myeloma Cells downregulatemiR-29b in dendritic cells to promote a tumor permissive inflammatory microenvironment and immune escape 42
Selective targeting of IRF4 by sytnthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 42
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 41
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 41
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing 40
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. 40
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells 40
Non-Coding RNAs in multiple myeloma bone disease pathophysiology 40
Primary large B-cell lymphoma involving the cerebellopontine angle mimic acoustic schwannoma: Role of MR Spectroscopy in differential diagnosis. A case report 39
Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia 39
MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile 39
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials 38
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma 38
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 37
Whole Body Magnetic Resonance and CT/PET in patients with multiple myeloma at staging and after treatment: personal experience in a longitudinal study 37
Targeting miR-21 in bone marrow stromal cells restores RANKL/OPG ratio within multiple myeloma microenvironment 37
MicroRNAs in multiple myeloma and related bone disease 37
Enumeration of IL-10-positive B cells from peripheral blood of Chronic Lymphocytic Leukemia patients 36
MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches 35
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome 35
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients 34
miR-29b targets HDAC4 and mediates activity of HDAC inhibitors in multiple myeloma cells 34
MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma 33
Venetoclax: A Game Changer in the Treatment of Younger AML Patients? 32
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 32
Totale 5.755
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.149
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.149
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022302 0 0 0 72 36 17 10 58 25 30 48 6
2022/2023723 223 37 33 46 69 54 4 49 103 38 51 16
2023/2024325 74 44 23 18 26 87 8 7 2 9 13 14
2024/20251.375 190 93 67 69 96 167 30 40 142 69 144 268
2025/20263.010 142 280 315 583 308 109 399 178 357 209 83 47
2026/2027720 25 176 359 160 0 0 0 0 0 0 0 0
Totale 6.777